Oncology · Small MoleculeRegulatory Approvalregulatorymid-term

Apotex submits supplemental application for Pomalidomide (ANDA 210164)

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/31/2026, 12:31:44 AM

Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of a supplemental application for Pomalidomide by Apotex signals an intent to enhance their oncology portfolio, which could disrupt existing market dynamics. Pharma strategy teams should closely monitor the FDA's review process and potential impacts on pricing and competition. Regulatory context from FDA (FDA AP — ROSUVASTATIN CALCIUM (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Apotex's submission on market dynamics and pricing strategies for Pomalidomide. The strongest clinical anchor is A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors (ClinicalTrials.gov), mechanism alignment (io ). In Oncology · Small Molecule, 6 regulatory and 5 competitive items passed relevance filtering for Apotex.

Competitive Pressure

The most relevant competitive pressure comes from Karyopharm's XPOVIO (Selinexor) NDA212306 Receives Approval Status from FDA (Humanexa Signals) — mechanism alignment (io ). Secondary pressure from FDA Grants Approval for Pomalidomide Supplement by Mylan. This submission indicates Apotex's intent to expand its portfolio in the oncology space, potentially increasing competition for existing Pomalidomide products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ROSUVASTATIN CALCIUM (SUPPL) (FDA). Entity match (apotex); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, PMDA. The FDA's review of this supplemental application could influence approval timelines and market entry strategies for similar products, impacting compliance and labeling considerations.

Key Risks

Elevated medium regulatory exposure for Apotex could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Increased competition from Apotex could lead to pricing pressures on existing Pomalidomide products, affecting revenue and market share for current manufacturers.
Portfolio teams should assess the impact of Apotex's submission on market dynamics and pricing strategies for Pomalidomide.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent approval announcements for this application.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AFATINIB DIMALEATE (ORIG)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — ANDA218552
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POSACONAZOLE (ORIG)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
[IBENTO][IBENTO]PMDA-ATC Blood Products Seminar 2026 for PPWG Applications open.
PMDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Modified Mini-PCNL Versus Standard PCNL for Complex Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Karyopharm's XPOVIO (Selinexor) NDA212306 Receives Approval Status from FDA
Humanexa Signalshigh relevance
Mechanism alignment (IO )
FDA Grants Approval for Pomalidomide Supplement by Mylan
Humanexa Signalshigh relevance
Entity match (pomalidomide)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Accepts Lenalidomide ANDA Submission from Torrent
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves JIDEYTRO (ZIDESAMTINIB) for Nuvalent Inc.
Humanexa Signalsmedium relevance
Moderate corpus alignment

Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-depende
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The dual role of exosomes in renal fibrosis and their potential for clinical translational applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Apotex
Pomalidomide

Commercial impact

medium

Increased competition from Apotex could lead to pricing pressures on existing Pomalidomide products, affecting revenue and market share for current manufacturers.

Regulatory impact

medium

The FDA's review of this supplemental application could influence approval timelines and market entry strategies for similar products, impacting compliance and labeling considerations.

What to watch

Monitor the FDA's review timeline and any subsequent approval announcements for this application.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.